A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

**Objective:** To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. **Methods:** A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-arm trial of brentuximab vedotin in 58 patients wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2016-10-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9820
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items